Description:
The purpose of the study is to assess the safety, tolerability and preliminary antitumor
activity of ZW25 in combination with docetaxel in participants with human epidermal growth
factor receptor 2 (HER2)-positive breast cancer, and ZW25 in combination with tislelizumab
and chemotherapy in participants with HER2-positive gastric/gastroesophageal Junction (GEJ)
adenocarcinoma
Title
- Brief Title: Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab
- Official Title: Phase 1b/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-HER2 Bispecific Antibody ZW25 in Combination With Chemotherapy With/Without Tislelizumab in Patients With Advanced HER2-positive Breast Cancer or Gastric/Gastroesophageal Junction Adenocarcinoma
Clinical Trial IDs
- ORG STUDY ID:
BGB-A317-ZW25-101
- NCT ID:
NCT04276493
Conditions
- Breast Cancer
- Gastric Cancer
- Gastroesophageal Junction Cancer
Interventions
Drug | Synonyms | Arms |
---|
ZW25 | | Cohort 1- ZW25 + Docetaxel |
Docetaxel | | Cohort 1- ZW25 + Docetaxel |
Tislelizumab | BGB-A317 | Cohort 2- ZW25 + Tiselizumab + Chemotherapy |
Capecitabine | | Cohort 2- ZW25 + Tiselizumab + Chemotherapy |
Oxaliplatin | | Cohort 2- ZW25 + Tiselizumab + Chemotherapy |
Purpose
The purpose of the study is to assess the safety, tolerability and preliminary antitumor
activity of ZW25 in combination with docetaxel in participants with human epidermal growth
factor receptor 2 (HER2)-positive breast cancer, and ZW25 in combination with tislelizumab
and chemotherapy in participants with HER2-positive gastric/gastroesophageal Junction (GEJ)
adenocarcinoma
Trial Arms
Name | Type | Description | Interventions |
---|
Cohort 1- ZW25 + Docetaxel | Experimental | ZW25 intravenous (IV) infusion followed by docetaxel IV infusion first-line therapy once every three weeks (Q3W) in female participants with metastatic breast cancer | |
Cohort 2- ZW25 + Tiselizumab + Chemotherapy | Experimental | ZW25 intravenous (IV) infusion followed by tiselizumab IV infusion and CAPOX chemotherapy (oral capecitabine + IV oxaliplatin) first-line therapy once every three weeks (Q3W) in participants with metastatic gastric / GEJ adenocarcinoma | - ZW25
- Tislelizumab
- Capecitabine
- Oxaliplatin
|
Eligibility Criteria
Key Inclusion Criteria:
1. Disease diagnosis and prior treatment:
1. Cohort 1 (the first-line breast cancer treatment cohort):
- Female participants with histologically or cytologically confirmed
unresectable, locally advanced, recurrent or metastatic adenocarcinoma of
the breast and candidate for chemotherapy. Locally recurrent disease must
not be amenable to resection with curative intent.
- Human epidermal growth factor receptor 2 (HER2) IHC 3+ or in situ
hybridization positive on the archival tumor tissue or fresh biopsy sample.
- Have not received previous systemic anticancer therapy for locally advanced
unresectable or metastatic disease.
2. Cohort 2 (the first-line gastric/gastroesophageal junction adenocarcinoma
treatment cohort):
- Histologically or cytologically confirmed unresectable, locally advanced,
recurrent or metastatic adenocarcinoma of the stomach or gastroesophageal
junction
- HER2 IHC 3+ or HER2 IHC 2+ together with in situ hybridization positive on
the archival tumor tissue or fresh biopsy sample.
- Have not received previous systemic anticancer therapy for locally advanced
unresectable or metastatic disease, including any approved or
investigational estimated glomerular filtration rate (EGFR) or anti-HER2
agents or vaccines, cytotoxic chemotherapy or checkpoint inhibitors
2. At least 1 measurable lesion as defined per RECIST Version 1.1
3. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1
4. Adequate organ function as indicated by the following laboratory values during
screening:
5. Left ventricular ejection fraction (LVEF) ≥ 50% at baseline as determined by either
echocardiogram or multigated acquisition scan (MUGA) (echocardiogram is the preferred
method) within 28 days before the first dose of study drug
Key Exclusion Criteria:
1. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or drug
specifically targeting T-cell co-stimulation or checkpoint pathways
2. History of approved or investigative tyrosine kinase/HER inhibitors in any treatment
setting
a. except trastuzumab with or without pertuzumab used in neoadjuvant or adjuvant
setting for Cohort 1
3. Active leptomeningeal disease or uncontrolled brain metastasis. Participants with
equivocal findings or with confirmed brain metastases are eligible for enrollment
provided that they are asymptomatic and radiologically stable without the need for
corticosteroid treatment for ≥ 4 weeks before the first dose of study drug
4. Any active malignancy ≤ 2 years before the first dose of study drug, except for the
specific cancer under investigation in this trial and any localized cancer that has
been treated curatively (eg, resected basal or squamous cell skin cancer, superficial
bladder cancer, carcinoma in situ of the cervix or breast)
5. Any condition that required systemic treatment with either corticosteroids (> 10 mg
daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days
before the first dose of study drug
Note: Participants who are currently or have previously been on any of the following
steroid regimens are not excluded:
1. Adrenal replacement steroid (dose ≤ 10 mg daily of prednisone or equivalent)
2. Topical, ocular, intra-articular, intranasal, or inhaled corticosteroid with minimal
systemic absorption
3. Short course (≤ 7 days) of corticosteroid prescribed prophylactically (eg, for
contrast dye allergy) or for the treatment of a non-autoimmune condition (eg,
delayed-type hypersensitivity reaction caused by contact allergen)
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Number of Participants experiencing Adverse Events (AEs) |
Time Frame: | Up to 12 months after the last dose of study drug. |
Safety Issue: | |
Description: | Defined as the proportion of participants who had a best overall response of complete response or partial response per the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. |
Secondary Outcome Measures
Measure: | Duration of response (DOR) |
Time Frame: | Up to 36 Months |
Safety Issue: | |
Description: | |
Measure: | Time to response (TRR) |
Time Frame: | Up to 36 Months |
Safety Issue: | |
Description: | Time from the start date of study drug to the first determination of an objective response by investigator per RECIST Version 1.1 |
Measure: | Progression-free survival (PFS) |
Time Frame: | Up to 36 Months |
Safety Issue: | |
Description: | Proportion of participants with best overall response of complete response, partial response, and stable disease by investigator per RECIST Version 1.1 |
Measure: | Overall survival (OS) |
Time Frame: | Up to 60 Months |
Safety Issue: | |
Description: | Time from the start date of study drug to the date of death due to any cause |
Measure: | Serum concentration of ZW25 as a function of time |
Time Frame: | Predose and immediately postdose |
Safety Issue: | |
Description: | |
Measure: | Observed maximum plasma concentration during a sample interval (Cmax (ng/mL) |
Time Frame: | Predose and immediately postdose |
Safety Issue: | |
Description: | |
Measure: | Observed time to maximum plasma concentration during a sampling interval (tmax(hour)) |
Time Frame: | Predose and immediately postdose |
Safety Issue: | |
Description: | |
Measure: | Terminal elimination half-life (t1/2(hour)) |
Time Frame: | Predose and immediately postdose |
Safety Issue: | |
Description: | |
Measure: | Area under the plasma concentration-time curve from time zero to the last measurable timepoint (AUC(0-t) (ng*h/mL)) |
Time Frame: | Predose and immediately postdose |
Safety Issue: | |
Description: | |
Measure: | Apparent clearance after oral administration (CL/F(L/hr)) |
Time Frame: | Predose and immediately postdose |
Safety Issue: | |
Description: | |
Measure: | Presence of anti-ZW25-antibodies |
Time Frame: | Predose and immediately postdose |
Safety Issue: | |
Description: | |
Measure: | Presence of ZW25 neutralizing antibodies |
Time Frame: | Predose and immediately postdose |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | BeiGene |
Last Updated
May 26, 2021